INCELL Inside
  • Product Line
  • Reg Med
    • Cell & Tissue Products
      • Regenerative & Stem Cells
      • Tissue-Derived Products
      • Reagents & Testing
      • INCELL Established Cell Lines
    • Tissue Collections & Kit Products
    • Storage of Cell & Tissue Products
    • Services: Manufacturing , Testing and R&D
      • Accelerated Product Development Services
      • Regenerative & Stem Cell Products
  • Micro
    • Microbiology & Vaccine Products
      • Microbiology Testing
        • Sterility: GMP and USP Compliant
        • Microbial Bioburden
        • Endotoxin/Pyrogen Testing
        • Mycoplasma Testing
        • Antimicrobial & Microbiological Testing
    • Vaccines and Microbiology Products
      • Microbiology & Vaccines Collaborations
    • Clinical Studies
  • Clinical
    • Clinical Trials
    • Personalized Medicine
  • About
    • Corporate
      • Contact
      • History
      • Mission
      • Registration, Licenses & Certificates
      • Memberships, Boards and Committees
    • Organization & Management
      • Board Members
        • Executive Managers
      • Key Alliances
        • Collaborative Business Model
    • Business Units & Activities
      • Regenerative Medicine
      • Media, Solutions & Kits
      • Microbiology & Vaccine Products
  • FAQ
  • News
    • Blog
    • Social Media
    • News & Newsworthy
      • Press Releases
      • Announcements
      • Community & Service Activities
        • Current Boards & Outreach
        • Archives
      • White Papers & Publications
        • White Papers
        • Publications & Links
      • Presentations
        • Recent
        • Archives
  • Jobs

Recent Posts

  • Letter from INCELL’s CEO
  • Dr. Mary Pat Moyer inducted to the National Academy of Engineering for her contribution to regenerative medicine, October 2019
INCELL is a products manufacturer and contract services provider with the mission to provide "Innovative Life Science Solutions™" in biomedicine.
« FMDIC Member, INCELL, Supports Quality System Conference
INCELL Sponsors 2016 Parenteral Drug Association (PDA) Meeting »

INCELL CEO Provides Testimony at FDA on Human Cells and Tissues Manufacturing

Published on: February 27, 2016 | Author: INCELL Online Team

FDA CBERSeptember 12-13, 2016 – Washington DC, USA. Dr. Mary Pat Moyer, INCELL CEO and Chief Science Officer, has been selected to speak in Session 1 at the US Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Public Hearing on Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products.

 

Categories: INCELL News | Tags: No tags |
« FMDIC Member, INCELL, Supports Quality System Conference
INCELL Sponsors 2016 Parenteral Drug Association (PDA) Meeting »

Product Categories

  • Collection, Transport and Processing Solutions
  • Compounded Drugs
  • Cryopreservation Media
    • EZ-CPZ ™ Cryopreservation Media Family
  • Culture Media
    • M3™ Media Family
  • Place Order
  • Proprietary Cell Lines
  • Sample Category
  • Services
  • Special Order
  • Tissue Collection Kits
  • Uncategorized

Recent Posts

  • Letter from INCELL’s CEO
  • Dr. Mary Pat Moyer inducted to the National Academy of Engineering for her contribution to regenerative medicine, October 2019
  • Dr. Moyer Addresses Orthopedic Physicians at AAOM National Meeting
  • INCELL Global Expansion
  • INCELL Sponsors WSCS in December 2016

Contact INCELL Corporation LLC

12734 Cimarron Path (Directions)
San Antonio, Texas 78249
Tel: 210-877-0100|Toll-free: 800.364.1765
Fax: 210-877-0200

Search Downloads

Privacy Policy | Sitemap | Contact

Copyright © 1993 - 2023. All Rights Reserved.

Designed by WebAuthorings.